Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

January 31, 2024

Study Completion Date

December 31, 2024

Conditions
NSCLCNSCLC Stage IVOligometastatic DiseaseNon Small Cell Lung CancerNon Small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung CancerNSCLC Stage IV Without EGFR/ALK MutationNon-Small Cell AdenocarcinomaNon-Small Cell Squamous Lung CancerNon-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor ReceptorSynchronous MetastasesMetachronous Metastasis
Interventions
RADIATION

Stereotactic Ablative Radiotherapy

"The prescribed dose of stereotactic ablative radiotherapy (SABR) will be chosen based on the target to be treated and its proximity to organs at risk(s):~Lung-peripheral 33-45 Gy/ 3 fractions~Lung-central/ultra-central 35-60 Gy/5 fractions~Mediastinal/supraclavicular node 35-45 Gy/5 fractions~Liver 45-54 Gy/3 fractions; 50-65 Gy/5 fractions~Bone non-spine 30-36 Gy/3 fractions; 35-50 Gy/5 fractions~Bone spine 30-33 Gy/3 fractions (SIB); 35-40 Gy/ 5 fractions (SIB)~Abdominal-pelvic node 33-39 Gy/ 3 fractions; 35-50 Gy/5 fractions~Adrenal gland 30-42 Gy/3 fractions; 35-50 Gy/5 fractions"

Trial Locations (1)

05100

RECRUITING

"Radiotherapy Oncology Centre S.Maria Hospital", Terni

All Listed Sponsors
collaborator

Paola Anselmo,MD

UNKNOWN

collaborator

Michelina Casale,PhD

UNKNOWN

collaborator

Fabio Trippa,MD

UNKNOWN

lead

"Radiotherapy Oncology Centre Santa Maria Hospital"

OTHER